Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.36 CAD
−27.75 M CAD
0.00 CAD
76.02 M
About ONCOLYTICS BIOTECH INC
Sector
Industry
CEO
Wayne F. Pisano
Website
Headquarters
Calgary
Founded
1998
FIGI
BBG000C3RN45
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
Once buyDidnt break to the downside, start of a new bullish trend, going for a second Elliot wave, bullish market structure, reaction at the support line
ONCY: Daily VCPSetup: RocketBase
VCP: 9W 38/4 4T
RS: 89
The posted chart contains a VCP (volatility contraction pattern). The first label "W" stands for weekly and shows the duration of the entire consolidation. In the middle label, the percentage of contractions is indicated (for example, "15/4"), with 15 repre
ONCY: Bullish Pennant (51%)Bullish Pennant (51%)
Pros:
Volume during post formation
Descending volume during triangle formation
Golden cross in blue
PPS above 50MA and 200MA
RS above 0
R/R ratio above 5
ATR ascending
250RSI above 50 and ascending
200MA ascending
Cona:
RS Flat
Target:
PT = 5.45$
Help how ever you can to keep
$ONCY initiated with a Buy at H.C. Wainwright -302.14% potentialOncolytics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio initiated coverage of Oncolytics Biotech with a Buy rating and $15 price target. The company is "on the cusp of demonstrating potential to upend the treatment paradigms of several cancers," Trucchio tells in
ONCY: Another risky biotech to considerLong term downtrend line broken. V shaped upswing with much increased volume. It has a well patented potential product that has great promise in assisting in treatment of difficult cancers. Like all small biotech companies there is often a lot of volatility and risk. I'm looking for a rise to 9-15.
ONCY - Long SetupCould flag again if it breaks above 3.66. Stop signal 3.19. Smaller position to offset stop risk. Target 4.23(acorn is already holding an active position in this)
ONC.CA: Descending TriangleDescending Triangle
Pros:
Descending Volume
R/R Ratio above 9
Descending ATR
200MA flat/ascending
PPS below 50MA
Cons:
250RSI still close to 50
PPS above 200MA
If confirmed
PT1 = 2,10
PT2 = 1,43
PT3 = 0,95
Bonus PT4 = 0,75
ONCY LONGMore information was necessary to form this decision. Time and patience. ONCY has stayed in the ascending channel well. I will buy here, but this is not financial advice.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ONC is 1.41 CAD — it has increased by 9.30% in the past 24 hours. Watch ONCOLYTICS BIOTECH INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSX exchange ONCOLYTICS BIOTECH INC stocks are traded under the ticker ONC.
ONC stock has risen by 21.55% compared to the previous week, the month change is a 1.44% rise, over the last year ONCOLYTICS BIOTECH INC has showed a −15.57% decrease.
We've gathered analysts' opinions on ONCOLYTICS BIOTECH INC future price: according to them, ONC price has a max estimate of 9.00 CAD and a min estimate of 3.50 CAD. Watch ONC chart and read a more detailed ONCOLYTICS BIOTECH INC stock forecast: see what analysts think of ONCOLYTICS BIOTECH INC and suggest that you do with its stocks.
ONC stock is 10.94% volatile and has beta coefficient of 0.81. Track ONCOLYTICS BIOTECH INC stock price on the chart and check out the list of the most volatile stocks — is ONCOLYTICS BIOTECH INC there?
Today ONCOLYTICS BIOTECH INC has the market capitalization of 108.67 M, it has increased by 14.16% over the last week.
Yes, you can track ONCOLYTICS BIOTECH INC financials in yearly and quarterly reports right on TradingView.
ONCOLYTICS BIOTECH INC is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
ONC earnings for the last quarter are −0.12 CAD per share, whereas the estimation was −0.10 CAD resulting in a −20.00% surprise. The estimated earnings for the next quarter are −0.12 CAD per share. See more details about ONCOLYTICS BIOTECH INC earnings.
ONCOLYTICS BIOTECH INC revenue for the last quarter amounts to 0.00 CAD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ONC net income for the last quarter is −9.54 M CAD, while the quarter before that showed −7.26 M CAD of net income which accounts for −31.52% change. Track more ONCOLYTICS BIOTECH INC financial stats to get the full picture.
No, ONC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 27.00 employees. See our rating of the largest employees — is ONCOLYTICS BIOTECH INC on this list?
Like other stocks, ONC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ONCOLYTICS BIOTECH INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ONCOLYTICS BIOTECH INC technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ONCOLYTICS BIOTECH INC stock shows the sell signal. See more of ONCOLYTICS BIOTECH INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.